Get started
Author

Christopher L. Miller

Observed name: Christopher A. Miller
ORCID: 0000-0003-4266-6700
Observed ORCID: 0000-0003-4266-6700
OpenAlex ID: A5132596751
Figure S3 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S8 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S4 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S5 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S10 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S6 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S7 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S1 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S3 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S2 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S2 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S4 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S7 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S9 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S6 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S1 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S5 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Table S9 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Data from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Figure S8 from Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
2026 · Rashmi Mishra, Foluso Ademuyiwa, et al.
Works count: 20
Citation count:
H-index:
I10-index:
Year
Topic
Type